Novel Indolyl-Hydrazone Kinase Inhibitors: Molecular Docking and X-ray Crystallographic Validation

Authors

  • Kelly C Department of Medicinal Chemistry, University College Dublin, Dublin, Ireland Author
  • Szabo L Department of Structural Biology, University of Debrecen, Debrecen, Hungary Author
  • Bergstrom G Department of Pharmacology, Lund University, Lund, Sweden Author

DOI:

https://doi.org/10.5281/zenodo.22644301

Keywords:

indolyl-hydrazone kinase inhibitors, molecular docking; X-ray crystallography, indolin-2-one pharmacophore, structure-based drug design

Abstract

Background: Protein kinases remain among the most extensively drugged enzyme families in oncology, and the indole and
indolin-2-one heterocycles, exemplified by the clinically approved multikinase inhibitor sunitinib, provide a structurally validated
hinge-binding pharmacophore. Fusion of these cores with the hydrazone functional group has generated an increasingly studied
class of indolyl-hydrazone kinase inhibitors. Objective: This narrative review synthesizes the published literature on
indolyl-hydrazone chemotypes directed against oncogenic kinases, with particular attention to the molecular docking
methodologies used to rationalize target engagement and the X-ray crystallographic evidence used to validate predicted binding
poses. Methods: Peer-reviewed studies reporting the synthesis, kinase-directed molecular docking, and, where available,
single-crystal X-ray diffraction of indolyl-hydrazone or closely related indolin-2-one-hydrazone compounds were identified and
synthesized thematically, covering pharmacophore rationale, docking outcomes, crystallographic validation, and
structure-activity relationships. Findings: Indolyl-hydrazone series have been docked against EGFR, PI3K isoforms, CDK2, AKT-1,
VEGFR-2, and Aurora B, with reported binding energies as favorable as -23.44 kcal/mol and enzymatic potencies spanning
sub-nanomolar to low-micromolar ranges; cellular anti-proliferative activity against breast and other tumor cell lines correlated
with docking-predicted target engagement in the most rigorously validated series. Experimental X-ray crystallography, though
applied to only a minority of reported compounds, has confirmed the solid-state hydrazone geometry of several lead structures and,
through the historical sunitinib-VEGFR2 co-crystal structure, provides a directly comparable structural template for hinge-binding
validation. Conclusions: Indolyl-hydrazone chemotypes constitute a chemically versatile and increasingly well-validated class of
kinase-inhibitor candidates, and wider adoption of experimental crystallography, including true protein-ligand co-crystal
structures, represents the most direct route to closing the current gap between computational docking prediction and structurally
confirmed binding modes.

References

Roskoski R Jr (2025) Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update. Pharmacological Research, 216:107723, DOI:10.1016/j.phrs.2025.107723.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3):229-263, DOI:10.3322/caac.21834.

McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences, 109(45):18281-18289, DOI:10.1073/pnas.1207759109. Enzymatic Aurora B kinase inhibitory potency (IC50, nM) of the lead fragment-based indolinone compound 3-17k relative to congeners 3-17a and 3-17d and the reference inhibitor CCT241736 (Xie et al., 2025).

Goodsell DS, Zardecki C, Di Costanzo L, Duarte JM, Hudson BP, Persikova I, Segura J, Shao C, Voigt M, Westbrook JD, Young JY, Burley SK (2019) RCSB Protein Data Bank: Enabling biomedical research and drug discovery. Protein Science, 29(1):52-65, DOI:10.1002/pro.3730.

Salama EE, Youssef MF, Aboelmagd A, Boraei ATA, Nafie MS, Haukka M, Barakat A, Sarhan AAM (2023) Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation. Pharmaceuticals, 16(12):1724, DOI:10.3390/ph16121724.

Al-Salem HS, Arifuzzaman M, Alkahtani HM, Abdalla AN, Issa IS, Alqathama A, Albalawi FS, Rahman AFMM (2020) A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor. Molecules, 25(19):4400, DOI:10.3390/molecules25194400.

Al-Warhi T, Almahli H, Maklad RM, Elsayed ZM, El Hassab MA, Alotaibi OJ, Aljaeed N, Ayyad RR, Ghabour HA, Eldehna WM, El-Ashrey MK (2023) 1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights. Molecules, 28(7):3203, DOI:10.3390/molecules28073203.

Hassan OM, Mahmood AAR, Hamzah AH, Tahtamouni LH (2022) Design, Synthesis, and Molecular Docking Studies of 5-Bromoindole-2-Carboxylic Acid Hydrazone Derivatives: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. ChemistrySelect, 7(46):e202203726, DOI:10.1002/slct.202203726.

Xie B, Shi M, Tang D, Yang S, Zeng Y, Nie L, Niu C (2025) Design and synthesis of novel indolinone Aurora B kinase inhibitors based on fragment-based drug discovery (FBDD). Molecular Diversity, 30(3):4015-4030, DOI:10.1007/s11030-025-11353-w.

Hassan EM, Soliman SM, Moneer EA, Hagar M, Barakat A, Haukka M, Rasheed H (2023) Synthesis, X-ray Structure, Hirshfeld, DFT Conformational, Cytotoxic, and Anti-Toxoplasma Studies of New Indole-Hydrazone Derivatives. International Journal of Molecular Sciences, 24(17):13251, DOI:10.3390/ijms241713251.

Pinzi L, Rastelli G (2019) Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences, 20(18):4331, DOI:10.3390/ijms20184331.

Sharma V, Gupta M (2022) Designing of kinase hinge binders: A medicinal chemistry perspective. Chemical Biology & Drug Design, 100(6):968-980, DOI:10.1111/cbdd.14024.

Dawood DH (2025) Therapeutic Insights of Indole Scaffold-Based Compounds as Protein Kinase Inhibitors. ChemistrySelect, 10(5):e202404767, DOI:10.1002/slct.202404767.

Prakash CR, Theivendren P, Raja S (2012) Indolin-2-Ones in Clinical Trials as Potential Kinase Inhibitors: A Review. Pharmacology & Pharmacy, 3(1):62-71, DOI:10.4236/pp.2012.31010.

Murugappan S, Dastari S, Jungare K, Barve NM, Shankaraiah N (2024) Hydrazide-hydrazone/hydrazone as enabling linkers in anti-cancer drug discovery: A comprehensive review. Journal of Molecular Structure, 1307:138012, DOI:10.1016/j.molstruc.2024.138012.

Mentese E, Caliskan N, Aksu D, Emirik M, Guner A, Yilmaz F (2026) Novel Adenine-Hydrazone Hybrids Against Human Lung Adenocarcinoma (A549): Design, Synthesis, Cellular Mechanistic Investigation and Molecular Docking Studies. Pharmaceuticals, 19(3):474, DOI:10.3390/ph19030474.

Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7:42717, DOI:10.1038/srep42717.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3):3-26, DOI:10.1016/S0169-409X(00)00129-0.

Downloads

Published

2025-12-21